financetom
Business
financetom
/
Business
/
Wellchange Completes $10 Million Stock Sale
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wellchange Completes $10 Million Stock Sale
Jan 17, 2025 2:31 PM

05:00 PM EST, 01/17/2025 (MT Newswires) -- Wellchange Holdings ( WCT ) late Friday said it has closed its public offering of 25 million shares at $0.40 each, raising about $10 million for the enterprise software company headquartered in Hong Kong.

Wellchange ( WCT ) plans to use the net proceeds for marketing and branding, expanding service capacity and general corporate purposes, according to its regulatory filing.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: AT&T Targets $40 Billion Shareholder Return in 2025 to 2027
Update: AT&T Targets $40 Billion Shareholder Return in 2025 to 2027
Dec 3, 2024
07:56 AM EST, 12/03/2024 (MT Newswires) -- (Updates with additional details from the fifth paragraph.) AT&T ( T ) said Tuesday that it expects more than $50 billion of free cash flow over the next three years and will return at least $40 billion to shareholders through dividends and buybacks. The company said it plans to maintain its current annualized...
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation
Dec 3, 2024
07:55 AM EST, 12/03/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday the US Food and Drug Administration has granted breakthrough therapy designation to sacituzumab tirumotecan, a treatment for certain times of non-small cell lung cancer. The designation is based on data from the phase 2 expansion group of a phase 1/2 study, as well as data from two...
Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials
Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials
Dec 3, 2024
07:59 AM EST, 12/03/2024 (MT Newswires) -- Aptose Biosciences ( APTO ) , a precision oncology company, on Tuesday said it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The NCI and Aptose will collaborate on developing Aptose's compound tuspetinib (TUS), an inhibitor of key signaling kinases involved in certain malignancies, in...
Canada's Scotiabank misses profit estimates on higher taxes, expenses
Canada's Scotiabank misses profit estimates on higher taxes, expenses
Dec 3, 2024
(Reuters) - Bank of Nova Scotia missed analysts' estimates for quarterly profit on Tuesday, hurt by higher taxes and elevated expenses related to compensation and technology. Adjusted profit rose 29% to C$2.12 billion ($1.51 billion). On a per share basis, the lender earned C$1.57, compared with analysts' expectations of C$1.60 per share, according to LSEG data. The quarter included impairment...
Copyright 2023-2026 - www.financetom.com All Rights Reserved